Overview Quote
Stock Activity
| Day Low - High | 86.94 - 87.88 |
| 52wk Low - High | 61.71 - 87.88 |
| Previous Close | 86.97 |
| Avg. Volume | 9,226,935 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 243.26 B |
| Div - Yield | 2.44 - 2.81 |
| Beta | 0.55 |
| PE (Forward) | 16.07 |
| Current Year Est. | 5.41 |
| Quarterly Earnings ESP |
0.71% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
170 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 1.40 | 1.33 | 5.41 | 5.78 |
| Number of Estimates | 10 | 10 | 16 | 13 |
| Low Estimate | 1.38 | 1.32 | 5.35 | 5.61 |
| High Estimate | 1.43 | 1.35 | 5.50 | NA |
| Year Ago EPS | 1.30 | 1.25 | 5.10 | 5.41 |
| EPS Growth | 8.00% | 6.48% | 6.13% | 6.75% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| JOHNSON & JOHNS | JNJ | 86.97 | ![]() |
![]() |
| ABBOTT LABS | ABT | 37.05 | ![]() |
![]() |
| ABBVIE INC | ABBV | 45.35 | ![]() |
![]() |
| ALLERGAN INC | AGN | 103.78 | ![]() |
![]() |
| ASTRAZENECA PLC | AZN | 51.19 | ![]() |
![]() |
| BRISTOL-MYERS | BMY | 42.21 | ![]() |
![]() |
| GLAXOSMITHKLINE | GSK | 51.72 | ![]() |
![]() |
| LILLY ELI & CO | LLY | 55.87 | ![]() |
![]() |
| MERCK & CO INC | MRK | 46.65 | ![]() |
![]() |
| NOVARTIS AG-ADR | NVS | 74.59 | ![]() |
![]() |
Sector:Medical>> Industry:LARGE CAP PHARMA
Zacks Commentary
Stock Market News for May 14, 2013
May 14, 2013
Stock Market News for May 13, 2013
May 13, 2013
Earnings Miss at SurModics
May 08, 2013
Earnings Plummet, Outlook Maintained at Sanofi
May 03, 2013
Wider-Than-Expected Loss at Pharmacyclics
May 02, 2013
Stocks Market News for May 1, 2013
May 01, 2013
Vertex Loss Lower, Kalydeco Outlook Up
May 01, 2013
Elan Narrows Y/Y Loss
Apr 25, 2013
Financials
| EPS TTM | 5.18 |
| Sales | 67,224 |
| Net Income | 10,440 |
| Price/Earnings | 16.79 |
| Price/Book | 3.64 |
| Price/Cash Flow | 13.38 |
| Price/Sales | 3.55 |
News
2 Red Flags for Merck`s Type 2 Diabetes Blockbuster - TheMotleyFool
May 15, 2013
Analyzing the Global CNS Market: 2013 Edition - M2
May 15, 2013
Buying Pfizer Stock Brings a Great Dividend - TheMotleyFool
May 15, 2013
DePuy ASR Lawsuit Update: DePuy Moves to Exclude Evidence of Recall in Federal Trial, Rottenstein Law Group LLP Reports - Prweb
May 15, 2013
Relypsa Announces Appointment of John Orwin as Chief Executive Officer - Businesswire
May 15, 2013
Shares of Johnson & Johnson Have Risen Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows
May 15, 2013
StockCall Scrutinizes PFE, MRK, JNJ, ABBV, and ZGNX - Accesswire-Tnw
May 15, 2013
Stryker`s Stock Looks Pricey - TheStreet.com
May 15, 2013
Broker Recommendations
| Current ABR | 1.95 |
| ABR (Last Week) | 1.95 |
| # of recs in ABR | 19 |
| Average Target Price | 84.77 |
| Industry Rank by ABR | 170 out of 265 |
| Rank in Industry | 1 out of 15 |

